The analyst rating is based on FOSUN PHARMA's 2025 performance, which met expectations and aligned with its Employee Stock Ownership Plan projections. While the company's revenue remained flat, net profit grew by 21.7%, mainly due to non-operating gains and investment income. The firm has raised revenue and net profit forecasts for the current and next year, but the target price was lowered from HKD31.6 to HKD25.4, maintaining an 'Outperform' rating.
